YD Bio Limited has entered into a Memorandum of Understanding to merge with EG BioMed, a biotechnology company specializing in DNA methylation-based cancer diagnostics and AI-driven biomarker analytics. The proposed combination aims to create an integrated oncology platform focused on early cancer detection, clinical data generation, and AI-enabled drug discovery. If completed, the merger could accelerate the transition toward a platform-based biotech organization anchored in clinically validated molecular data. EG BioMed is expected to contribute advanced DNA methylation diagnostics, AI biomarker algorithms, and clinical laboratory infrastructure, supporting both diagnostics commercialization and therapeutic innovation. The transaction is anticipated to close in 2026, pending the finalization of definitive agreements and other customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9618934-en) on January 06, 2026, and is solely responsible for the information contained therein.